AVO is a provider of internationally endorsed technology for advanced radiotherapy to treat common and rare cancers. Around the world today, more than 50% of cancer patients receive radiotherapy treatment as part of their cancer care.
The continued challenge clinicians face is to deliver adequate amounts of radiation to the tumour while sparing non diseased, healthy tissue and vital organs like the heart, lungs, spinal cord, liver, bladder and kidneys. The advantage of sparing healthy tissue is to reduce the risk of secondary cancer from the treatment itself. Detrimental, serious and expensive to treat complications of irradiating healthy tissue are well documented in the medical literature.
AVO is a leader in affordable and accessible proton beam therapy along with other technologies like SD-IORT™. AVO's focus is to develop advanced, cost effective and patient-friendly radiotherapy treatments which are clinically superior to those currently available.
In April 2013, AVO announced it's potential acquisition of ADAM-Geneva, a CERN spin-off company based on the CERN campus, home of the LHC and the discovery of the 'God particle.'
AVO’s ADAM-Geneva physics team have created a compact linear accelerator that will be the next generation of targeted cancer treatment. The team‘s aim is to dramatically reduce the cost of delivering enhanced radiotherapy in the clinical setting. Thus, AVO makes radiotherapy more accessible to more patients with lower side effects and better outcomes. Currently, the cost and size of proton beam therapy machines and the necessary edifices to house them explain why there are only 32 centres in the world.
In addition, AVO is the market leader in the UK and Ireland in providing a fully managed radiotherapy service to the NHS and private sector to treat early stage breast cancer in one dose in one day.
AVO has exclusivity to the technology, SD-IORT™, for early stage breast cancer which can also be used to deliver electronic brachytherapy in one or more doses (called fractions) to treat non-melanoma skin cancer, endometrial cancer, and rectal cancer. This mobile service provides therapeutic radiation treatments on demand with minimal toxicity to surrounding healthy tissue, without the complex handling, resource logistics and costs associated with using radioactive isotopes. The result is greater cost effectiveness and increased patient convenience.
For more information about the ADAM acquisition and proton beam therapy, see CNBC video with AVO's Chief Executive
AVO is an AIM-listed company registered and operating in England.